Jan Cerny is an Oncology physician affiliated with UMass Memorial Health Care. OpenAlex indexes 395 publications with 4,309 citations (h-index 36); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Lake Ave N
Dept Of Hematology/oncology
Worcester, MA 016550002
Telephone
774-442-3903Provider last certified this registry record 3 Nov 2020.
Clinical trials
- Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
Sponsor: University of Massachusetts, Worcester
- Collection of Blood and/or Bone Marrow for Investigation and Characterization of Normal and Abnormal Cell Growth
Sponsor: University of Massachusetts, Worcester
- Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.
Sponsor: University of Massachusetts, Worcester
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- GENZYME CORPORATIONProgram year20241 payment
- E.R. Squibb & Sons, L.L.C.Program year20232 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
41%Fluoroquinolone Antibacterial15%Levofloxacin100%Part D<11 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor15%Valacyclovir100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
32%Kinase inhibitor17%Jakafi100%Part D<11 patientsNucleoside Metabolic Inhibitor15%Inqovi100%Part D<11 patientsNervous system
15%Gabapentinoids15%Gabapentin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Gerard Aurigemma, MD
UMass Memorial Health Care
Richard Irwin, MD
UMass Memorial Health Care
Craig Lilly, MD
UMass Memorial Health Care
David Keefe, MD
UMass Memorial Health Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”